These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 24813528)

  • 1. Epigenetic deregulation in myeloid malignancies.
    Meldi KM; Figueroa ME
    Transl Res; 2015 Jan; 165(1):102-14. PubMed ID: 24813528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
    Lowder JN; Taverna P; Issa JP
    Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
    [No Abstract]   [Full Text] [Related]  

  • 3. Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.
    Leone G; D'Alò F; Zardo G; Voso MT; Nervi C
    Curr Med Chem; 2008; 15(13):1274-87. PubMed ID: 18537607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.
    Khan H; Vale C; Bhagat T; Verma A
    Semin Hematol; 2013 Jan; 50(1):16-37. PubMed ID: 23507481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic regulators and their impact on therapy in acute myeloid leukemia.
    Pastore F; Levine RL
    Haematologica; 2016 Mar; 101(3):269-78. PubMed ID: 26928248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
    Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
    Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
    [No Abstract]   [Full Text] [Related]  

  • 8. Myelodysplastic syndromes (MDSs) and acute myelogenous leukemia (AML) comprise a closely linked continuum of malignant hematologic diseases. Introduction.
    Baylin SB; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S1-3. PubMed ID: 16341235
    [No Abstract]   [Full Text] [Related]  

  • 9. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
    Hou HA; Tien HF
    Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic therapies in MDS and AML.
    Griffiths EA; Gore SD
    Adv Exp Med Biol; 2013; 754():253-83. PubMed ID: 22956506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Stahl M; Gore SD; Vey N; Prebet T
    Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
    Ungerstedt JS
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies.
    Craddock C
    Cytotherapy; 2011 May; 13(5):516-7. PubMed ID: 21375421
    [No Abstract]   [Full Text] [Related]  

  • 15. The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia.
    Gonzalez-Lugo JD; Chakraborty S; Verma A; Shastri A
    Semin Hematol; 2021 Jan; 58(1):56-65. PubMed ID: 33509444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia.
    Przybilla J; Hopp L; Lübbert M; Loeffler M; Galle J
    Epigenetics; 2017; 12(10):886-896. PubMed ID: 28758855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia.
    Voso MT; Lo-Coco F; Fianchi L
    Curr Opin Oncol; 2015 Nov; 27(6):532-9. PubMed ID: 26352541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
    Lübbert M; Kuendgen A
    Cancer; 2015 Feb; 121(4):498-501. PubMed ID: 25336205
    [No Abstract]   [Full Text] [Related]  

  • 20. Epigenetic therapy in myelodysplastic syndromes.
    Musolino C; Sant'antonio E; Penna G; Alonci A; Russo S; Granata A; Allegra A
    Eur J Haematol; 2010 Jun; 84(6):463-73. PubMed ID: 20192987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.